This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
BAYRY's Kerendia Label Expansion Application Gets Priority Review
by Zacks Equity Research
Bayer wins FDA Priority Review for Kerendia label expansion in CKD tied to type I diabetes after strong phase III data.
REGNNegative Net Change JNJPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
by Zacks Equity Research
DYN shares jump 10% after launching a phase III study of z-rostudirsen in Duchenne muscular dystrophy patients amenable to exon 51 skipping.
DYNNo Net Change LQDANegative Net Change IMCRNegative Net Change INDVPositive Net Change
biotechs
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
by Ahan Chakraborty
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
by Zacks Equity Research
STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA filing plans.
BIIBPositive Net Change LQDANegative Net Change STOKNegative Net Change IMCRNegative Net Change
biotechs medical
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
by Zacks Equity Research
Atara stock soars 82% as the FDA outlines a regulatory pathway for its lead product candidate, tab-cel, reviving hopes for potential U.S. approval, after two prior CRLs.
ATRAPositive Net Change LQDANegative Net Change IMCRNegative Net Change INDVPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
by Zacks Equity Research
Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.
LQDANegative Net Change IMVTPositive Net Change IMCRNegative Net Change INDVPositive Net Change
biotechs
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
by Zacks Equity Research
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
RHHBYPositive Net Change MRKPositive Net Change EXELPositive Net Change NTRANegative Net Change
biotechnology biotechs medical pharmaceuticals
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
by Zacks Equity Research
TG Therapeutics gains on strong Briumvi sales growth, higher 2026 revenue guidance and advancing late-stage studies in RMS.
TGTXNegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVPositive Net Change
biotechs medical
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
by Zacks Equity Research
Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.
LQDANegative Net Change IMCRNegative Net Change ERNANegative Net Change INDVPositive Net Change
biotechnology biotechs cell-therapy medical oncology-screening pharmaceuticals
FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy
by Zacks Equity Research
ImmunityBio's shares rise after the FDA accepts a filing to expand Anktiva's use in bladder cancer, with a decision due by January 2027.
IMCRNegative Net Change IBRXNegative Net Change INDVPositive Net Change
biotechs medical